Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Mar 28, 2026

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production
10:20

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Published on: October 26, 2018

12.0K

New England Compounding Center Indictment.

Joe Cabaleiro

    International Journal of Pharmaceutical Compounding
    |December 22, 2015
    PubMed
    Summary
    This summary is machine-generated.

    This review examines lapses in United States Pharmacopeia (USP) standards and pharmacy law compliance, highlighted by the New England Compounding Center indictment. It serves as a guide for compounding pharmacies to assess and improve their practices.

    Related Concept Videos

    Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

    Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

    224
    Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
    224
    Production of Pharmaceuticals01:30

    Production of Pharmaceuticals

    51
    Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
    51
    Drug Regulation01:25

    Drug Regulation

    3.3K
    Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
    3.3K
    Insensitive Nuclei Enhanced by Polarization Transfer (INEPT)01:15

    Insensitive Nuclei Enhanced by Polarization Transfer (INEPT)

    1.2K
    Insensitive Nuclei Enhanced by Polarization Transfer (INEPT) is an advanced Nuclear Magnetic Resonance (NMR) technique specifically designed to detect and enhance the signals of low-abundance nuclei, such as carbon-13 and nitrogen-15, in small molecules. The fundamental principle behind INEPT is the transfer of polarization from a more abundant and highly polarizable nucleus, typically hydrogen-1, to the low-abundance nucleus of interest. This process effectively boosts the NMR signal of the...
    1.2K
    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

    216
    Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
    216
    EDTA: Auxiliary Complexing Reagents01:26

    EDTA: Auxiliary Complexing Reagents

    1.6K
    EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...
    1.6K

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA.

    International journal of pharmaceutical compounding·2021
    Same author

    Performing a United States Pharmacopeia Chapter <800> Compliant Assessment of Risk.

    International journal of pharmaceutical compounding·2020
    Same author

    Root Cause Analysis, Part 2: STERILE COMPOUNDING.

    International journal of pharmaceutical compounding·2016
    Same author

    The Home Field Disadvantage.

    International journal of pharmaceutical compounding·2016
    Same author

    Root Cause Analysis, Part 1: Nonsterile Compounding.

    International journal of pharmaceutical compounding·2016
    Same author

    Pharmacy Compounding Accreditation Board: past, present, and future.

    International journal of pharmaceutical compounding·2015
    Same journal

    Compounding and Stability Study of Dipyridamole and Clopidogrel Pediatric Oral Suspensions.

    International journal of pharmaceutical compounding·2026
    Same journal

    Nanoemulsion Reformulation of Nitrosylcobalamin (NO-Cbl) Enhances Solubility, Stability, and Anti-Tumor Potency.

    International journal of pharmaceutical compounding·2026
    Same journal

    Chemical and Microbiological Stability Supporting Extended BUDs in Pentravan® Based Transdermal Preparations.

    International journal of pharmaceutical compounding·2026
    Same journal

    Stability Evaluation of Compounded Benzocaine, Lidocaine, and Tetracaine in VersaPro™ Cream Base.

    International journal of pharmaceutical compounding·2026
    Same journal

    Formulation and In-Vitro Characterization of Gastroretentive Effervescent Floating Tablets of Meloxicam.

    International journal of pharmaceutical compounding·2026
    Same journal

    Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities.

    International journal of pharmaceutical compounding·2026
    See all related articles

    Area of Science:

    • Pharmaceutical Compounding
    • Pharmacy Law and Regulation
    • Infection Control

    Background:

    • The New England Compounding Center indictment stemmed from a fungal meningitis outbreak.
    • The outbreak was linked to contaminated compounded methylprednisolone for epidural injections.
    • This highlights critical failures in sterile compounding practices.

    Purpose of the Study:

    • To review lapses in United States Pharmacopeia (USP) standards and pharmacy law compliance.
    • To analyze the specific failures leading to the New England Compounding Center indictment.
    • To provide a gap analysis tool for compounding facilities.

    Main Methods:

    • Review of the New England Compounding Center indictment details.
    • Analysis of alleged violations of USP standards and pharmacy law.

    More Related Videos

    Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases
    11:03

    Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

    Published on: May 29, 2017

    10.5K
    Optogenetic Functional MRI
    06:06

    Optogenetic Functional MRI

    Published on: April 19, 2016

    15.6K

    Related Experiment Videos

    Last Updated: Mar 28, 2026

    Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production
    10:20

    Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

    Published on: October 26, 2018

    12.0K
    Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases
    11:03

    Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

    Published on: May 29, 2017

    10.5K
    Optogenetic Functional MRI
    06:06

    Optogenetic Functional MRI

    Published on: April 19, 2016

    15.6K
  • Comparative assessment framework for compounding compliance.

    • Main Results:

    • Identified significant deviations from USP <797> and <71> standards.
    • Highlighted failures in aseptic technique, environmental monitoring, and personnel training.
    • Demonstrated a direct link between non-compliance and patient harm.

    Conclusions:

    • Compounding pharmacies must rigorously adhere to USP standards and pharmacy law.
    • Implementing robust quality management systems is essential for patient safety.
    • Continuous evaluation and improvement of compounding practices are necessary to prevent future outbreaks.